Neuland Laboratories reports strong Q2 FY26 financial performance

Neuland Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025, revealing a substantial increase in total income and profitability. Consolidated total income for Q2 FY26 reached Rs. 516.1 crore, a 63.7% year-over-year (YoY) increase, with EBITDA at Rs. 156.9 crore (138.8% YoY) and PAT at Rs. 96.5 crore (201.6% YoY). This performance was primarily attributed to commercial projects within the Contract Manufacturing Solutions (CMS) segment.

For the half year ended September 30, 2025, the consolidated total income stood at Rs. 816.7 crore, a 7.5% YoY increase, with EBITDA at Rs. 199.1 crore and PAT at Rs. 110.2 crore. The company emphasized a steady shift from low-margin Prime to high-margin Specialty and CMS segments. Net Debt improved significantly, standing at Rs. (-6.6) crore at the end of Q2 FY26.

Operational highlights included Unit-2 receiving an EIR post-FDA inspection in Q1, one USDMF filed in Q2 FY26, and Unit-1 receiving the Sword of Honour from the British Safety Council for outstanding Health & Safety practices. Neuland Laboratories continues to expand its capabilities and global presence, with a total reactor volume of 11,74,000 Liters and over 995 DMFs filed worldwide.